US6610493B1
(en)
*
|
1993-06-17 |
2003-08-26 |
Brigham And Women's Hospital |
Screening compounds for the ability to alter the production of amyloid-β peptide
|
US5955317A
(en)
*
|
1993-01-25 |
1999-09-21 |
Takeda Chemical Industries, Ltd. |
Antibodies to β-amyloids or their derivatives and use thereof
|
ES2155099T3
(es)
|
1993-10-27 |
2001-05-01 |
Elan Pharm Inc |
Animales transgenicos que albergan alelos app que presentan una mutacion sueca.
|
US6365414B1
(en)
|
1994-08-26 |
2002-04-02 |
The General Hospital Corporation |
Vitro system for determining formation of Aβ amyloid
|
AU8083094A
(en)
*
|
1994-10-19 |
1996-05-15 |
General Hospital Corporation, The |
A diagnostic assay for alzheimer's disease: assessment of abeta abnormalities
|
US5972634A
(en)
*
|
1994-10-19 |
1999-10-26 |
The General Hospital Corporation |
Diagnostic assay for Alzheimer's disease: assessment of Aβ abnormalities
|
US6114133A
(en)
*
|
1994-11-14 |
2000-09-05 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
|
US7427392B1
(en)
*
|
1994-11-14 |
2008-09-23 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
|
US5786180A
(en)
*
|
1995-02-14 |
1998-07-28 |
Bayer Corporation |
Monoclonal antibody 369.2B specific for β A4 peptide
|
CA2213094A1
(en)
*
|
1995-02-15 |
1996-08-22 |
Takeda Chemical Industries, Ltd. |
Use of vinpocetine derivatives for inhibiting production or secretion of amyloid beta protein
|
WO1997026913A1
(en)
*
|
1996-01-26 |
1997-07-31 |
The Trustees Of Columbia University In The City Of New York |
A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
|
AU743827B2
(en)
*
|
1997-04-09 |
2002-02-07 |
Intellect Neurosciences, Inc. |
Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
|
US8173127B2
(en)
*
|
1997-04-09 |
2012-05-08 |
Intellect Neurosciences, Inc. |
Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
|
US6207370B1
(en)
*
|
1997-09-02 |
2001-03-27 |
Sequenom, Inc. |
Diagnostics based on mass spectrometric detection of translated target polypeptides
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
AU2006202899B2
(en)
*
|
1997-12-02 |
2009-10-29 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidogenic disease
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7964192B1
(en)
*
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
US7790856B2
(en)
*
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6743427B1
(en)
|
1997-12-02 |
2004-06-01 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6761888B1
(en)
*
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
US20030147882A1
(en)
*
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
US20040234976A1
(en)
*
|
1998-09-24 |
2004-11-25 |
Gurney Mark E. |
Alzheimer's disease secretase, app substrates therefor, and uses therefor
|
US6844148B1
(en)
|
1998-09-24 |
2005-01-18 |
Pharmacia & Upjohn Company |
Alzheimer's disease secretase, APP substrates therefor, and uses therefor
|
EP1939297A1
(de)
|
1998-09-24 |
2008-07-02 |
Pharmacia & Upjohn Company LLC |
Alzheimerkrankheit-Sekretase
|
EP1115874B1
(de)
|
1998-09-24 |
2009-01-07 |
Pharmacia & Upjohn Company LLC |
Alzheimersche krankheit sekretase
|
US6699671B1
(en)
|
1998-09-24 |
2004-03-02 |
Pharmacia & Upjohn Company |
Alzheimer's disease secretase, APP substrates therefor, and uses therefor
|
US6972318B1
(en)
*
|
1998-10-30 |
2005-12-06 |
Holtzman Jordan L |
Complex of a chaperone protein with amyloid
|
US7115410B1
(en)
*
|
1999-02-10 |
2006-10-03 |
Elan Pharmaceuticals, Inc. |
β-secretase enzyme compositions and methods
|
US7456007B1
(en)
|
1998-12-31 |
2008-11-25 |
Elan Pharmaceuticals, Inc. |
β-secretase enzyme compositions and methods
|
JP5122705B2
(ja)
*
|
1999-01-25 |
2013-01-16 |
ミナーヴァ・バイオテクノロジーズ・コーポレーション |
神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出
|
GB2364059B
(en)
|
1999-02-10 |
2004-01-14 |
Elan Pharm Inc |
Beta-Secretase enzyme compositions and methods
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
JP5249482B2
(ja)
*
|
1999-06-16 |
2013-07-31 |
ボストン・バイオメデイカル・リサーチ・インステイテユート |
インビボのβ−アミロイドレベルの免疫学的制御
|
US20090162883A1
(en)
*
|
1999-09-23 |
2009-06-25 |
Pharmacia & Upjohn Company |
Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
|
US7514408B1
(en)
|
1999-12-02 |
2009-04-07 |
Elan Pharmaceuticals, Inc. |
β-secretase enzyme compositions and methods
|
ATE423221T1
(de)
|
2000-06-13 |
2009-03-15 |
Univ Boston |
Verwendung von mass-matched nukleotide in der analyse von oligonukleotidmischungen sowie in der hoch-multiplexen nukleinsäuresequenzierung
|
US6686449B2
(en)
|
2000-06-30 |
2004-02-03 |
Pharmacia & Upjohn Company |
Mutant presenilin 1 polypeptides
|
EP1538163A3
(de)
*
|
2000-11-01 |
2005-06-15 |
Insight Biotechnology Limited |
Phophoryliert Amyloid-Beta 1-43 Proteine und deren Verwendung bei der Behandlung der Alzheimer Krankheit
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
TWI255272B
(en)
*
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US6815175B2
(en)
|
2001-03-16 |
2004-11-09 |
Cornell Research Foundation, Inc. |
Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
|
US6906169B2
(en)
*
|
2001-05-25 |
2005-06-14 |
United Biomedical, Inc. |
Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
|
US7060270B2
(en)
*
|
2001-11-02 |
2006-06-13 |
Diagenics International Corporation |
Methods and compositions of monoclonal antibodies specific for beta-amyloid proteins
|
AR038568A1
(es)
*
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
Anticuerpos anti-a beta y su uso
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US7122374B1
(en)
*
|
2002-04-09 |
2006-10-17 |
Takaomi Saido |
Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
|
US20040049134A1
(en)
*
|
2002-07-02 |
2004-03-11 |
Tosaya Carol A. |
System and methods for treatment of alzheimer's and other deposition-related disorders of the brain
|
US20070003552A1
(en)
*
|
2002-07-09 |
2007-01-04 |
Gebbink Martijn F B |
Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
|
EP1380290A1
(de)
|
2002-07-09 |
2004-01-14 |
Universitair Medisch Centrum Utrecht |
Cross-Beta-Strukturweg und seine therapeutische Relevanz
|
EP1911765A3
(de)
*
|
2002-07-24 |
2008-04-23 |
Innogenetics N.V. |
Vorbeugung, Behandlung und Diagnose von Erkrankungen im Zusammenhang mit Beta-Amyloid-Bildung und/oder -Aggregation
|
AU2003279216A1
(en)
*
|
2002-10-09 |
2004-05-04 |
Rinat Neuroscience Corp. |
Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
|
KR100520495B1
(ko)
*
|
2002-10-23 |
2005-10-11 |
한국과학기술연구원 |
베타아밀로이드 특이 단일 클론 항체 및 그의 제조방법
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US20060188512A1
(en)
*
|
2003-02-01 |
2006-08-24 |
Ted Yednock |
Active immunization to generate antibodies to solble a-beta
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
US20040223912A1
(en)
*
|
2003-05-07 |
2004-11-11 |
Montalto Michael Christopher |
Compositions and methods for non-invasive imaging of soluble beta-amyloid
|
EP1631561B1
(de)
|
2003-05-07 |
2010-08-18 |
General Electric Company |
Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid
|
EP1480041A1
(de)
*
|
2003-05-22 |
2004-11-24 |
Innogenetics N.V. |
Verfahren zur Voraussage, zur Diagnose und zur vergleichenden Diagnose von Alzheimer
|
TWI306458B
(en)
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
CA2538220A1
(en)
*
|
2003-09-09 |
2005-03-24 |
Takeda Pharmaceutical Company Limited |
Use of antibody
|
US7807157B2
(en)
|
2004-02-20 |
2010-10-05 |
Intellect Neurosciences Inc. |
Monoclonal antibodies and use thereof
|
TWI355389B
(en)
|
2004-07-30 |
2012-01-01 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide a
|
AU2005293752A1
(en)
*
|
2004-10-13 |
2006-04-20 |
Ablynx N.V. |
Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
|
ES2396555T3
(es)
*
|
2004-12-15 |
2013-02-22 |
Janssen Alzheimer Immunotherapy |
Anticuerpos que reconocen péptido beta amiloide
|
WO2006066171A1
(en)
*
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Amyloid βετα antibodies for use in improving cognition
|
PE20061329A1
(es)
*
|
2004-12-15 |
2006-12-08 |
Neuralab Ltd |
Anticuerpos ab humanizados para mejorar la cognicion
|
ES2259270B1
(es)
*
|
2005-03-09 |
2007-11-01 |
Consejo Superior De Investigaciones Cientificas |
Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
|
US20090202980A1
(en)
*
|
2005-03-21 |
2009-08-13 |
Crossbeta Biosciences B.V. |
Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
|
UY29504A1
(es)
|
2005-04-29 |
2006-10-31 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
|
US20080249606A1
(en)
*
|
2005-07-13 |
2008-10-09 |
Martijn Frans Ben Gerard Gebbink |
Methods for Determining the Effect of a Treatment on the Cross-Beta Structure Content of a Protein; Selection of Treatments and Uses Thereof
|
US8114832B2
(en)
*
|
2005-07-13 |
2012-02-14 |
Crossbeta Biosciences B.V. |
Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
|
CA2615028A1
(en)
|
2005-07-13 |
2007-01-18 |
Crossbeta Biosciences B.V. |
Cross-.beta. structure binding compounds
|
RU2008120027A
(ru)
*
|
2005-10-21 |
2009-11-27 |
Мерк энд Ко., Инк. (US) |
Анти-addl моноклональное антитело и его применение
|
RS53270B2
(sr)
|
2005-11-30 |
2018-05-31 |
Abbvie Deutschland |
Monoklonalna antitela protiv amiloidnog beta proteina i njihova upotreba
|
AU2006319358B2
(en)
|
2005-11-30 |
2012-01-19 |
AbbVie Deutschland GmbH & Co. KG |
Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
|
NO345996B1
(no)
*
|
2005-12-12 |
2021-12-13 |
Ac Immune Sa |
A beta 1-42-spesifikke monoklonale antistoffer med terapeutiske egenskaper.
|
CN102659943B
(zh)
|
2005-12-12 |
2015-07-01 |
豪夫迈·罗氏有限公司 |
抗体可变区的糖基化
|
EP2007800A1
(de)
*
|
2006-03-17 |
2008-12-31 |
Crossbeta Biosciences B.V. |
Verfahren zur bindung von kreuz-beta-strukturen durch chaperone
|
US8784810B2
(en)
*
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
PL2468770T3
(pl)
*
|
2006-07-14 |
2018-07-31 |
Ac Immune S.A. |
Humanizowane przeciwciało przeciw amyloidowi beta
|
WO2008045962A2
(en)
*
|
2006-10-10 |
2008-04-17 |
Mayo Foundation For Medical Education And Research |
Methods and materials related to anti-a (beta) antibodies
|
US7745222B2
(en)
*
|
2006-10-13 |
2010-06-29 |
General Electric Company |
Amyloid binding assays
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP1944315A1
(de)
*
|
2007-01-11 |
2008-07-16 |
Philipps-Universität Marburg |
Prophylaxe und Therapie von Morbus Alzheimer und anderen Demenzerkrankungen
|
PL2104682T3
(pl)
*
|
2007-01-11 |
2017-03-31 |
Michael Bacher |
Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
|
CA2678194A1
(en)
|
2007-02-09 |
2008-08-14 |
Tokyo Metropolitan Organization For Medical Research |
Anti-human brak (cxcl14) monoclonal antibody and use thereof
|
EP2486928A1
(de)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Verfahren zur Behandlung von Amyloidosen
|
AU2008220785B2
(en)
|
2007-03-01 |
2013-02-21 |
Vivoryon Therapeutics N.V. |
New use of glutaminyl cyclase inhibitors
|
US9656991B2
(en)
|
2007-04-18 |
2017-05-23 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
US8003097B2
(en)
*
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
JP2011526240A
(ja)
*
|
2007-04-18 |
2011-10-06 |
ヤンセン アルツハイマー イミュノセラピー |
脳アミロイド血管症の予防および治療
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
SG182192A1
(en)
*
|
2007-06-12 |
2012-07-30 |
Ac Immune Sa |
Humanized antibodies to amyloid beta
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
ES2498040T3
(es)
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
|
ES2442500T3
(es)
*
|
2007-10-02 |
2014-02-11 |
Csl Limited |
Método de purificación de anticuerpos terapéuticos y método de uso
|
ES2445590T3
(es)
|
2007-10-05 |
2014-03-04 |
Genentech, Inc. |
Uso de anticuerpo anti-amiloide beta en enfermedades oculares
|
US20100297012A1
(en)
*
|
2007-10-05 |
2010-11-25 |
Andrea Pfeifer |
Humanized antibody
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
EP2058000A1
(de)
*
|
2007-11-08 |
2009-05-13 |
Crossbeta Biosciences B.V. |
Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
|
EP2058001A1
(de)
*
|
2007-11-08 |
2009-05-13 |
Crossbeta Biosciences B.V. |
Steigerung der Immunogenizität von Antigenen
|
US20110014182A1
(en)
*
|
2007-12-11 |
2011-01-20 |
Philippe Marc Louis Alard |
Antigen binding proteins
|
WO2009136499A1
(ja)
|
2008-05-08 |
2009-11-12 |
武田薬品工業株式会社 |
Aβオリゴマー測定法
|
CN102203124A
(zh)
*
|
2008-07-25 |
2011-09-28 |
雅培制药有限公司 |
淀粉状蛋白β肽类似物,其寡聚物,用于制备的方法以及包括所述类似物或寡聚物的组合物,及其用途
|
EP2149380A1
(de)
*
|
2008-07-29 |
2010-02-03 |
Medivet Pharma, S.L. |
Tierärztliche Immuntherapiezusammensetzung für altersbedingte kognitive Dysfunktion
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
EP2258398A1
(de)
*
|
2009-05-26 |
2010-12-08 |
Araclón Biotech, S. L. |
Albumin/Amyloidpeptid-Konjugate und deren Verwendungen
|
EP2475428B1
(de)
|
2009-09-11 |
2015-07-01 |
Probiodrug AG |
Heterocyclische derivate als glutaminylcyclase-hemmer
|
JP2013505438A
(ja)
*
|
2009-09-18 |
2013-02-14 |
プロビオドルグ エージー |
アミロイドβペプチドの検出のための新規アッセイ
|
JP6026284B2
(ja)
|
2010-03-03 |
2016-11-16 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤
|
JP5688745B2
(ja)
|
2010-03-10 |
2015-03-25 |
プロビオドルグ エージー |
グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤
|
MX336196B
(es)
|
2010-04-15 |
2016-01-11 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
US8541596B2
(en)
|
2010-04-21 |
2013-09-24 |
Probiodrug Ag |
Inhibitors
|
BR112013002297A2
(pt)
|
2010-07-30 |
2016-05-24 |
Ac Immune Sa |
anticorpos humanizados seguros e funcionais
|
WO2012024187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
WO2012123563A1
(en)
|
2011-03-16 |
2012-09-20 |
Probiodrug Ag |
Benz imidazole derivatives as inhibitors of glutaminyl cyclase
|
EP2691393B1
(de)
|
2011-03-31 |
2016-09-14 |
Pfizer Inc |
Neue bicyclische pyridinone
|
EP2511296A1
(de)
*
|
2011-04-12 |
2012-10-17 |
Araclón Biotech, S. L. |
Antikörper, Kit und Verfahren zur Bestimmung von Amyloidpeptiden
|
WO2012172449A1
(en)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactams as beta secretase inhibitors
|
US9926353B2
(en)
|
2011-07-19 |
2018-03-27 |
New York University |
Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
|
WO2013013056A1
(en)
|
2011-07-19 |
2013-01-24 |
New York University |
Method for treating amyloid disease
|
JP6043355B2
(ja)
|
2011-08-31 |
2016-12-14 |
ファイザー・インク |
ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
|
JP6110937B2
(ja)
|
2012-05-04 |
2017-04-05 |
ファイザー・インク |
APP、BACE1、およびBACE2の阻害剤としての複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
|
MD20140130A2
(ro)
|
2012-06-29 |
2015-04-30 |
Pfizer Inc. |
4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
|
US9260455B2
(en)
|
2012-09-20 |
2016-02-16 |
Pfizer Inc. |
Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
UA110688C2
(uk)
|
2012-09-21 |
2016-01-25 |
Пфайзер Інк. |
Біциклічні піридинони
|
WO2014091352A1
(en)
|
2012-12-11 |
2014-06-19 |
Pfizer Inc. |
Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
|
WO2014097038A1
(en)
|
2012-12-19 |
2014-06-26 |
Pfizer Inc. |
CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
|
EP2956458B1
(de)
|
2013-02-13 |
2017-08-09 |
Pfizer Inc |
Heteroarylsubstituierte hexahydropyrano[3,4-d][1,3]thiazin-2-amin-verbindungen
|
US9233981B1
(en)
|
2013-02-15 |
2016-01-12 |
Pfizer Inc. |
Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
WO2014128585A1
(en)
|
2013-02-19 |
2014-08-28 |
Pfizer Inc. |
Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
|
US9102752B2
(en)
|
2013-03-15 |
2015-08-11 |
United Biomedical, Inc. |
Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
|
JP6425717B2
(ja)
|
2013-10-04 |
2018-11-21 |
ファイザー・インク |
ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
|
EP3083618B1
(de)
|
2013-12-17 |
2018-02-21 |
Pfizer Inc |
Neuartige 3,4-disubstituierte-1h-pyrrolo[2,3-b]pyridine und 4,5-disubstituierte 7h-pyrrolo[2,3-c]pyridazine als lrrk2-hemmer
|
PE20161364A1
(es)
|
2014-04-01 |
2016-12-25 |
Pfizer |
CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
|
WO2015155626A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
|
US10131669B2
(en)
|
2014-07-24 |
2018-11-20 |
Pfizer Inc. |
Pyrazolopyrimidine compounds
|
DK3177624T3
(da)
|
2014-08-06 |
2019-07-01 |
Pfizer |
Imidazopyridazinforbindelser
|
DK3253755T3
(da)
|
2015-02-03 |
2020-09-28 |
Pfizer |
Hidtil ukendte cyclopropabenzofuranyl-pyridopyrazindioner
|
SG10201912333PA
(en)
|
2015-06-17 |
2020-02-27 |
Pfizer |
Tricyclic compounds and their use as phosphodiesterase inhibitors
|
HRP20220304T1
(hr)
|
2015-06-24 |
2022-05-13 |
F. Hoffmann - La Roche Ag |
Anti-transferinska receptorska protutijela s prilagođenim afinitetom
|
JP6873980B2
(ja)
|
2015-09-14 |
2021-05-19 |
ファイザー・インク |
LRRK2阻害薬としての新規のイミダゾ[4,5−c]キノリンおよびイミダゾ[4,5−c][1,5]ナフチリジン誘導体
|
WO2017051276A1
(en)
|
2015-09-24 |
2017-03-30 |
Pfizer Inc. |
N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
|
JP2018531924A
(ja)
|
2015-09-24 |
2018-11-01 |
ファイザー・インク |
テトラヒドロピラノ[3,4−d][1,3]オキサジン誘導体、およびbace阻害剤としてのその使用
|
EP3353174A1
(de)
|
2015-09-24 |
2018-08-01 |
Pfizer Inc |
N-[2-(3-amino-2,5-dimethyl-1,1-dioxid-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)]-1,3-thiazol-4-yl-amide als bace-hemmer
|
EP3356406A1
(de)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispezifische antikörper gegen menschliches cd20/gegen den menschlichen transferrinrezeptor und verfahren zur verwendung
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
AU2017223132B2
(en)
|
2016-02-23 |
2019-12-05 |
Pfizer Inc. |
6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
|
KR102470497B1
(ko)
|
2016-07-01 |
2022-11-23 |
화이자 인코포레이티드 |
신경계 및 신경변성 질환을 치료하기 위한 5,7-디히드로-피롤로-피리딘 유도체
|
CN111201226B
(zh)
|
2017-03-10 |
2022-07-22 |
辉瑞大药厂 |
环状被取代的咪唑并[4,5-c]喹啉衍生物
|
CA3056030A1
(en)
|
2017-03-10 |
2018-09-13 |
Pfizer Inc. |
Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
|
US20230137562A1
(en)
|
2017-06-07 |
2023-05-04 |
Adrx, Inc. |
Tau aggregation inhibitors
|
KR20200013783A
(ko)
|
2017-06-22 |
2020-02-07 |
화이자 인코포레이티드 |
디히드로-피롤로-피리딘 유도체
|
EP3668886A2
(de)
|
2017-08-18 |
2020-06-24 |
Adrx, Inc. |
Peptidinhibitoren der tau-aggregation
|
ES2812698T3
(es)
|
2017-09-29 |
2021-03-18 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
ES2942837T3
(es)
|
2018-03-23 |
2023-06-07 |
Pfizer |
Derivados de azaespiro piperazina
|
WO2020015637A1
(zh)
|
2018-07-17 |
2020-01-23 |
江苏恒瑞医药股份有限公司 |
抗Abeta抗体、其抗原结合片段及应用
|
CA3176743A1
(en)
*
|
2019-04-04 |
2020-10-08 |
The Royal Institution For The Advancement Of Learning / Mcgill University |
Use of a.beta.34 to assess alzheimer's disease progression
|
US20230021187A1
(en)
|
2019-11-19 |
2023-01-19 |
Foundation For Biomedical Research And Innovation At Kobe |
Cross-linked product of amyloid-b protein (ab) as potential substitute for amylospheroids (aspd) and analysis of aspd
|